
CADL
Candel Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.040
Open
6.970
VWAP
6.87
Vol
598.93K
Mkt Cap
368.33M
Low
6.735
Amount
4.11M
EV/EBITDA(TTM)
--
Total Shares
29.76M
EV
286.24M
EV/OCF(TTM)
--
P/S(TTM)
--
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Show More
4 Analyst Rating

213.39% Upside
Wall Street analysts forecast CADL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CADL is 22.00 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy

213.39% Upside
Current: 7.020

Low
15.00
Averages
22.00
High
25.00

213.39% Upside
Current: 7.020

Low
15.00
Averages
22.00
High
25.00
Brookline
Kemp Dolliver
Buy
initiated
$25
2025-07-09
Reason
Brookline
Kemp Dolliver
Price Target
$25
2025-07-09
initiated
Buy
Reason
Brookline analyst Kemp Dolliver initiated coverage of Candel Therapeutics with a Buy rating and $25 price target. Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies, the analyst tells investors in a research note. The firm says the company's lead candidate CAN-2409 met the primary endpoint in a Phase 3 trial in newly-diagnosed localized prostate cancer in intermediate- or high-risk patients, setting the stage for an application filing in Q4 of 2026.
H.C. Wainwright
Buy
initiated
$23
2025-06-30
Reason
H.C. Wainwright
Price Target
$23
2025-06-30
initiated
Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2025-04-11
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2025-04-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2025-03-14
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2025-03-14
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2025-02-26
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2025-02-26
Reiterates
Strong Buy
Reason
Canaccord Genuity
John Newman
Strong Buy
Maintains
$20 → $25
2025-02-26
Reason
Canaccord Genuity
John Newman
Price Target
$20 → $25
2025-02-26
Maintains
Strong Buy
Reason
Canaccord analyst John Newman raised the firm's price target on Candel Therapeutics to $25 from $20 and keeps a Buy rating on the shares. The firm said its CAN-2409 shows significant median Overall Survival improvement from the control arm.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Candel Therapeutics Inc (CADL.O) is -8.87, compared to its 5-year average forward P/E of -4.86. For a more detailed relative valuation and DCF analysis to assess Candel Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.86
Current PE
-8.87
Overvalued PE
-1.40
Undervalued PE
-8.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.54
Current EV/EBITDA
-6.75
Overvalued EV/EBITDA
0.67
Undervalued EV/EBITDA
-5.75
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
705.56
Current PS
0.00
Overvalued PS
1700.09
Undervalued PS
-288.97
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+2.89%
-8.13M
Operating Profit
FY2025Q1
YoY :
-189.76%
7.38M
Net Income after Tax
FY2025Q1
YoY :
-146.43%
0.13
EPS - Diluted
FY2025Q1
YoY :
+2.06%
-8.62M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.9K
USD
1
3-6
Months
1.2M
USD
6
6-9
Months
1.6M
USD
14
0-12
Months
442.9K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
544.8K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
4.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.9K
USD
1
3-6
Months
1.2M
USD
6
6-9
Months
1.6M
USD
14
0-12
Months
442.9K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CADL News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
08:08:02
Candel Therapeutics receives EMA Orphan Designation for CAN-2409

2025-07-09 (ET)
2025-07-09
08:18:29
Candel Therapeutics announces addition to multiple Russell Indexes

2025-06-24 (ET)
2025-06-24
09:07:46
Candel Therapeutics prices 3.2M shares at $4.67 in registered direct offering

Sign Up For More Events
Sign Up For More Events
News
9.0
07-24NewsfilterPinnedCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
2.0
07-16BenzingaASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
4.0
06-30BenzingaHC Wainwright & Co. Assumes Candel Therapeutics at Buy, Announces Price Target of $23
Sign Up For More News
People Also Watch

ARTNA
Artesian Resources Corp
33.070
USD
-0.69%

FNLC
First Bancorp Inc
25.660
USD
+3.14%

GRAF
Graf Global Corp
10.510
USD
0.00%

ITOS
Iteos Therapeutics Inc
10.170
USD
+0.20%

IBEX
Ibex Ltd
29.790
USD
-2.38%

PKE
Park Aerospace Corp
17.610
USD
-1.07%

REI
Ring Energy Inc
0.799
USD
+0.25%

SLI
Standard Lithium Ltd
2.640
USD
-1.12%

MAMA
Mama's Creations Inc
9.030
USD
-1.10%

CZNC
Citizens & Northern Corp
19.220
USD
+0.21%
FAQ

What is Candel Therapeutics Inc (CADL) stock price today?
The current price of CADL is 7.02 USD — it has increased 0.29 % in the last trading day.

What is Candel Therapeutics Inc (CADL)'s business?

What is the price predicton of CADL Stock?

What is Candel Therapeutics Inc (CADL)'s revenue for the last quarter?

What is Candel Therapeutics Inc (CADL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Candel Therapeutics Inc (CADL)'s fundamentals?

How many employees does Candel Therapeutics Inc (CADL). have?
